// App-Quantinova.ai

: Balance of risk and benefit of spironolactone according to renal function in heart failure patients with preserved ejection fraction

Researchers

Presenter

  • I E Beldhuis

Principal Investigators

  • P L Myhre

  • B Claggett

  • K Damman

  • J C Fang

  • E F Lewis

  • E O'Meara

  • B Pitt

  • S J Shah

  • A A Voors

Medical Centers

  • Brigham and Women's Hospital, Channing Division of Network Medicine, Boston, United States of America

  • University Medical Center Groningen, Department of Epidemiology, Groningen, Netherlands

  • University of Utah School of Medicine, Salt Lake City, United States of America

  • Medecine, Montreal Heart Institute, Montreal, Canada

  • University of Michigan School of Medicine, Ann Arbor, United States of America

  • Northwestern University Medical Center, Division of Cardiology, Chicago, United States of America

Locations

  • Netherlands

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Spironolactone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • National Heart, Lung, and Blood Institute

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved